Lundbeck’s Asedebart Receives the US FDA Orphan Drug Designation for Endogenous Cushing’s Syndrome

Shots: The US FDA has granted Orphan Drug Designation (ODD) to asedebart (Lu AG13909) for the treatment of endogenous Cushing’s syndrome Lundbeck is evaluating efficacy and safety of asedebart in proof-of-concept trials for Cushing’s disease & classic congenital adrenal hyperplasia (CAH)  Asedebart is a humanized anti-ACTH monoclonal antibody that blocks ACTH signaling at the adrenal glands, reducing the secretion of glucocorticoids, mineralocorticoids & androgens Ref: PRnewswire  |  Image: Lundbeck  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Lundbeck’s Asedebart Receives the US FDA Orphan Drug Designation for Endogenous Cushing’s Syndrome appeared first on PharmaShots.